| Type of Material: | Thesis |
| Title: | A novel process development based on recombinant DNA technology for the production of HIV entry inhibitor molecule |
| Researcher: | Ravikanth Reddy Kosana |
| Guide: | Murali K R Tummuru |
| Department: | Faculty of Biotechnology |
| Publisher: | Jawaharlal Nehru Technological University, Hyderabad |
| Place: | Hyderabad |
| Year: | 2016 |
| Language: | English |
| Subject: | AIDS | Biotechnology and Applied Microbiology | HIV | Life Sciences | Microbiology | Recombinant DNA technology | Biotechnology | Engineering and Technology |
| Dissertation/Thesis Note: | PhD; Faculty of Biotechnology, Jawaharlal Nehru Technological University, Hyderabad, Hyderabad; 2016 |
| Fulltext: | Shodhganga |
| 000 | 00000ntm a2200000ua 4500 | |
| 001 | 454233 | |
| 003 | IN-AhILN | |
| 005 | 2024-07-29 17:31:40 | |
| 008 | __ | 240729t2016||||ii#||||g|m||||||||||eng|| |
| 035 | __ | |a(IN-AhILN)th_454233 |
| 040 | __ | |aJNTU_500028|dIN-AhILN |
| 041 | __ | |aeng |
| 100 | __ | |aRavikanth Reddy Kosana|eResearcher |
| 110 | __ | |aFaculty of Biotechnology|bJawaharlal Nehru Technological University, Hyderabad|dHyderabad|ein|0U-0017 |
| 245 | __ | |aA novel process development based on recombinant DNA technology for the production of HIV entry inhibitor molecule |
| 260 | __ | |aHyderabad|bJawaharlal Nehru Technological University, Hyderabad|c2016 |
| 300 | __ | |a199p.|dDVD |
| 502 | __ | |cFaculty of Biotechnology, Jawaharlal Nehru Technological University, Hyderabad, Hyderabad|d2016|bPhD |
| 518 | __ | |dMarch 2016|oDate of Award |
| 518 | __ | |oDate of Registration|d2007-01-01 |
| 520 | __ | |aAcquired Immunodeficiency Syndrome (AIDS) is a pandemic disease caused by infection with Human Immunodeficiency Virus (HIV). HIV primarily infects the cells which play a vital role in the human immune system like CD4+ T cells, dendritic cells and macrophages and destroys these cells leading to life threatening opportunistic infections. Current medications for HIV infection consists of highly active antiretroviral therapy (HAART) which has been highly effective but with no permanent cure. These antiretroviral drugs are designed to interfere with the replication cycle of HIV. However, the success of the current therapy is limited due to the rapid emergence of drug resistant mutant viruses, complex dosage regimen, side effects, expensive treatment and limited medications in majority of the countries. Vaccine is the best choice to treat this syndrome which is economical and would not require daily treatment. But, HIV-1 remained as a complex target for a vaccine development till now due to newlineits genome div |
| 650 | __ | |aBiotechnology|2UGC |
| 650 | __ | |aEngineering and Technology|2AIU |
| 653 | __ | |aAIDS |
| 653 | __ | |aBiotechnology and Applied Microbiology |
| 653 | __ | |aHIV |
| 653 | __ | |aLife Sciences |
| 653 | __ | |aMicrobiology |
| 653 | __ | |aRecombinant DNA technology |
| 700 | __ | |eGuide|aMurali K R Tummuru |
| 856 | __ | |uhttp://shodhganga.inflibnet.ac.in/handle/10603/291074|yShodhganga |
| 905 | __ | |afromsg |
User Feedback Comes Under This section.